Something seems afoot with the EU approval of Janssen Pharmaceutical Cos.’s controversial new drug for treatment-resistant depression Spravato (esketamine).
The European Medicines Agency has received “written interventions” from third parties relating to the agency’s October recommendation that the drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?